FLT3 and acute myeloid leukemia: Therefore, phase I/II clinical studies of the monotherapy protocols with the common FLT3 inhibitors (like Lestaurtinib, Midostaurin, and Quizartinib) in AML patients had shown a poor clinical response as the drug resistance rapidly developed after the starting of these treatment regimens owing to like these types of mutation [6].